To read the full story, subscribe or sign in.

Japan's Peptidream partners with Kleo Pharmaceuticals to develop IO therapies

Aug. 2, 2017

HONG KONG – Tokyo-based Peptidream Inc. is partnering with New Haven, Conn.-based Kleo Pharmaceuticals Inc. to develop immuno-oncology (IO) products in multiple indications.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Oct. 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Oct. 7, 2025.

ESGCT 2025: Redefining CAR T cells across cancer and autoimmunity

BioWorld Science

As the many challenges facing cell therapies are being addressed, the CAR T field continues to evolve beyond its original design of T cells engineered to target...

Chemistry Nobel’s applications could include biopharma, though translation is slow

BioWorld Science

The 2025 Nobel Prize in Chemistry “is a story full of holes, but with enormous capacity to absorb all your attention,” Heiner Linke told reporters. “And other...

Cellular senescence may trigger MS progression

BioWorld Science

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s European Committee for Treatment and...